• 2 min read • Author: Fabian Dawson • Print • Privacy & Disclaimer

Why MustGrow is a Must Have

MustGrow Biologics Corp. shares are on fire as investor enthusiasm surges over the company’s transition from research and development to active commercialization of its sustainable crop protection products.

Disseminated on behalf of MustGrow Biologics Corp.

  • MustGrow Biologics has secured over 100 patents, both pending and issued, in the agricultural biotech industry.
  • Its flagship product, TerraSante, is already available in several major U.S. states, with approvals in additional states underway.
  • Global leader Bayer has committed $35-40 million toward the development and regulatory approval efforts.

Since the IBE in September at the Muskoka Capital Event, MustGrow’s stock price appreciated to an impressive high of $2.50 CAD before more recently experiencing a healthy retracement into the $1.50 - $1.75 range and closing around $2 at market close today.

MustGrow's unique capital structure, with no outstanding warrants, an extremely tight share structure, heavy insider ownership, and no capital raised in the last three years, demonstrates a low burn rate and management's prudent use of capital. All these factors play a big part in the stock price movement.

Company at a Glance

TSXV: MGRO

MustGrow is an agriculture biotech company focused on creating natural, eco-friendly solutions to protect crops and improve soil health. They use the mustard plant’s natural defense properties to develop products that help farmers grow food sustainably.

“Our recent approvals in key U.S. states to sell our product mark a significant milestone, opening up a new category of investors interested in early-stage revenue companies, rather than just development-stage opportunities…This has undoubtedly contributed to the recent surge in our share price.”
- Jamieson Bondarenko, Capital Advisor, MustGrow Biologics Corp.
💰
$103M
Market Cap¹
🔷
55.7M
Shares
🏆
$1.04
Picked²
  1. As of market close on Thursday November 14, 2024
  2. As of market open on Monday September 30, 2024 after being selected as a Top Pick at the CEM Muskoka Capital Event*

Why is this happening?

Sales of its TerraSante™ biofertility product have commenced in the U.S., including California, Florida, Arizona, Idaho, Oregon, and Washington, with plans to scale up commercialization in 2025 and 2026. MustGrow’s commercial agreement for its soil biopesticide, TerraMG™, is opening markets in Europe, the Middle East, and Africa. This partnership not only validates MustGrow’s technology but also provides significant financial backing, with Bayer committing $35-40 million for development and registration efforts.

MustGrow is expanding its intellectual property portfolio, now boasting 112 issued and pending patents as it shifts focus from R&D to commercialization—a significant increase from 84 patents in March 2023. MustGrow has strategically secured contract manufacturers to handle initial production, allowing for a smoother transition to market and eliminating capital expenditure for a pilot plant. This also paves the way for scalability on a global level.

Visit Website

Further reading

MustGrow Provides 2024 Pipeline Update

MustGrow Receiving Funding from Agriculture and Agri-Food Canada for Human & Animal Health Applications

MustGrow Receives Florida Registration for TerraSanteᵀᴹ Biofertility Product

Privacy & Disclaimers

General Disclaimer

Investor Breakout publishes this editorial content (“Editorial Content”) featuring certain issuers ("Featured Issuers") and is for informational purposes. The Editorial Content is derived from interviews with the Featured Issuer and Investor Breakout's Editor-in-Chief and information provided by the Featured Issuer. Such information does not constitute representations or opinions of Investor Breakout, or its directors, officers, shareholders, employees, or consultants (collectively "Representatives"). The Featured Issuer is wholly and exclusively responsible for the validity of the information forming the Editorial Content. Investor Breakout has not independently verified or otherwise investigated the validity of such information. Neither Investor Breakout, nor any of its Representatives, guarantee, make any representation of, or take any responsibility for, the accuracy or completeness of any such information. 

The publication of Editorial Content does not constitute an endorsement, recommendation, or opinion regarding the merits of any issuer, its business, products, services or securities. Additionally, Investor Breakout does not endorse or recommend the business, products, services or securities of any issuer mentioned herein. Neither this communication nor Investor Breakout purport to provide a complete analysis of the Featured Issuer or its financial position. Investor Breakout is not, and does not purport to be, a broker-dealer or registered investment adviser.

This communication is not intended as, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.  This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a substitute for professional financial consultation. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Featured Issuer. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the Featured Issuer's public filings on its SEDAR+ profile and/or other government filings. Investing in securities is speculative and carries a high degree of risk and you could lose all or some of your investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results.  Any action a reader takes as a result of the information presented herein is his or her own responsibility. 

Forward-Looking Information

This publication may contain statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking information in this publication is based on Investor Breakout’s understanding of the issuers, as of the date of this publication. 

The forward-looking information contained in this publication represents Investor Breakout’s understanding of the issuers, as of the date of this publication and, accordingly, is subject to change after such date. There can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.  Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Investor Breakout undertakes no obligation to update these forward-looking statements in the event that Investor Breakout’s beliefs, estimates or opinions, or other factors, should change.

Marketing

We have social media channels that utilize first and third-party vendor remarketing tracking cookies, including the Meta, LinkedIn, and X remarketing cookies. This means we will show ads to you across the Internet, specifically on Facebook, Instagram, LinkedIn, and X. This data may also be shared with trusted third party vendors that utilize this data to create promotion campaigns for other related companies. As always, we respect your privacy and are not collecting any identifiable information through the use of any other third party remarketing system.

The first and third-party vendors, whose services we use — will place cookies on web browsers in order to serve ads based on past visits to our website. This allows us to make major announcements and continue to market our services to those who have shown interest in our service.

You may opt out of the automated collection of information by third-party ad networks for the purpose of delivering advertisements tailored to your interests, by visiting the consumer opt-out page for the Self-Regulatory Principles for Online Behavioural Advertising.